Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 15/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 13/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.36 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17503801 | 0.90 | KDM4C (0.39) | LATS1LATS2KDM4C | |
| SCHEMBL17503666 | 0.88 | KDM4C (0.42) | LATS1LATS2KDM4CKDM4EKDM4A | |
| SCHEMBL17503833 | 0.81 | LATS1 (0.40) | LATS1LATS2KDM4CPIP4K2A | |
| SCHEMBL16095427 | 0.80 | KDM4C (0.50) | LATS1LATS2KDM4CPIP4K2AKDM4E | |
| SCHEMBL17503791 | 0.80 | LATS1 (0.38) | LATS1LATS2KDM4CKDM4EKDM4A | |
| SCHEMBL17503742 | 0.79 | LATS1 (0.44) | LATS1LATS2KDM4C | |
| SCHEMBL17503682 | 0.79 | CSNK2A2 (0.39) | LATS1LATS2KDM4CKDM4EKDM4A | |
| SCHEMBL17517204 | 0.78 | PDE5A (0.44) | LATS1LATS2KDM4C | |
| SCHEMBL17517199 | 0.77 | KDM4C (0.39) | LATS1LATS2KDM4C | |
| SCHEMBL17503824 | 0.77 | LATS1 (0.39) | LATS1LATS2KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-08 | — | — | US | claimed |
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2970211-B1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2970211-B1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | LATS1 4166/4885LATS2 4386/4885KDM4C 9/4885 |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | LATS1 4166/4885LATS2 4386/4885KDM4C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.